Efficacy and safety of OBI‐1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A

By  

HAEMOPHILIA, Vol. 21, Iss. 2, 2015-03 ,pp. : 162-170

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Evidence behind Inhibitor Treatment with Porcine Factor VIII

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 32, Iss. 1, 2002-05 ,pp. : 5-8

Karger

Access to resources Recommend Favorite

Recombinant full‐length factor VIII (FVIII) and extended half‐life FVIII products in prophylaxis – new insight provided by pharmacokinetic modelling

By  

HAEMOPHILIA, Vol. 21, Iss. 3, 2015-05 ,pp. : 300-306

John Wiley & Sons Inc

Access to resources Recommend Favorite

Expression and characterization of recombinant human milk fat globule-EGF factor VIII

By              

International Journal of Molecular Medicine, Vol. 28, Iss. 6, 2011-01 ,pp. : 1071-1076

Spandidos Publications

Access to resources Recommend Favorite

Pharmacokinetic properties of BAY 81‐8973, a full‐length recombinant factor VIII

By  

HAEMOPHILIA, Vol. 21, Iss. 6, 2015-11 ,pp. : 766-771

John Wiley & Sons Inc

Access to resources Recommend Favorite